Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Experimental Medicine and Rheumatology Group have had published today the results of their IMPROVE study in Lancet Haematology.

The IMPROVE study set out to investigate in those with chronic lymphocytic leukaemia (CLL) if having a 3-week pause in existing Bruton tyrosine kinase inhibitor (BTKi) therapy during COVID-19 vaccination - improved the immune response to the vaccination.

The results suggest that pausing BTKi around the time of vaccination is not beneficial for immunity and should not be recommended in clinical practice.

https://www.sciencedirect.com/science/article/pii/S2352302625000080